{"id":496218,"date":"2021-05-20T07:03:30","date_gmt":"2021-05-20T11:03:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/"},"modified":"2021-05-20T07:03:30","modified_gmt":"2021-05-20T11:03:30","slug":"expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/","title":{"rendered":"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors<\/b><\/p>\n<p class=\"bwalignc\"><i>Article in <\/i>Journal of Drugs in Dermatology<i> provides a framework for integrating DecisionDx-SCC into patient care<\/i><\/p>\n<p>FRIENDSWOOD, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCastle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert panel in the <i>Journal of Drugs in Dermatology. <\/i>The publication provides a framework for integrating DecisionDx-SCC into clinical practice.\n<\/p>\n<p>\nTreatment plan decisions in SCC are based upon the likelihood of an individual patient\u2019s tumor to metastasize. Data from previous studies has demonstrated that DecisionDx-SCC, Castle\u2019s prognostic 40-GEP test designed to use a patient\u2019s tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors, is a significant, independent predictor of risk, compared to existing traditional clinical and pathologic staging systems.\n<\/p>\n<p>\nThe article, titled \u201cClinical Considerations for Integrating Gene Expression Profiling into Cutaneous Squamous Cell Carcinoma Management,\u201d describes the findings of a multidisciplinary expert panel, representing backgrounds from academic medical centers and community practices. The panel also included specialties clinicians, such as Mohs surgeons, surgical oncologists and a radiation oncologist. The panel reviewed traditional risk assessment practices, guidelines and expert recommendations on DecisionDx-SCC. The panel also focused on decision-making points, where information from DecisionDx-SCC might inform the clinical management of patients with SCC and one or more risk factors.\n<\/p>\n<p><i>Study findings: <\/i><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDecision points supported by DecisionDx-SCC test results include:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nnodal evaluation\n<\/li>\n<li>\nadjuvant radiation therapy\n<\/li>\n<li>\nfollow-up and surveillance\n<\/li>\n<\/ul>\n<\/li>\n<li>\nThe panel determined that the additional information provided by DecisionDx-SCC could:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nhelp avoid unnecessary treatment and surveillance\n<\/li>\n<li>\nallow healthcare providers to increase treatment intensity or follow-up as needed\n<\/li>\n<li>\ninform if and when to refer a patient for medical, surgical, or radiation oncology\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n\u201cThis is an exciting time in the management of high-risk squamous cell carcinoma patients,\u201d said study author, Sherrif Ibrahim, M.D., Ph.D., Mohs surgeon and associate professor in the department of dermatology at The University of Rochester Medical Center. \u201cProgress has been made with clinicopathologic risk factor assessment. However, potential remains for these assessments to overestimate or underestimate risk. Gene expression profile testing assists us in assessing the biologic risk of individual tumors and providing personalized care for our patients, which may lead to risk appropriate reduction of treatment or increased treatment intensity and more appropriate referrals.\u201d\n<\/p>\n<p><b>About DecisionDx-SCC<\/b><\/p>\n<p>\nDecisionDx-SCC is a 40-gene expression profile test that uses an individual patient\u2019s tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1, 2A or 2B risk category, predicts individual metastatic risk to inform risk-appropriate management.\n<\/p>\n<p>\nPeer-reviewed publications have demonstrated that DecisionDx-SCC is an independent predictor of metastatic risk and that integrating DecisionDx-SCC with current prognostic methods can add positive predictive value to clinician decisions regarding staging and management.\n<\/p>\n<p>\nMore information about the test and disease can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleTestInfo.com&amp;esheet=52432717&amp;newsitemid=20210520005207&amp;lan=en-US&amp;anchor=www.CastleTestInfo.com&amp;index=1&amp;md5=b323d485f08e8a3823d0ac42ba31e4ac\">www.CastleTestInfo.com<\/a>.\n<\/p>\n<p><b>About Castle Biosciences<\/b><\/p>\n<p>\nCastle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx<sup>\u00ae<\/sup>-Melanoma, DecisionDx<sup>\u00ae<\/sup>-CM<i>Seq),<\/i> cutaneous squamous cell carcinoma (DecisionDx<sup>\u00ae<\/sup>-SCC), suspicious pigmented lesions (DecisionDx<sup>\u00ae <\/sup>DiffDx\u2122-Melanoma) and uveal melanoma (DecisionDx<sup>\u00ae<\/sup>-UM, DecisionDx<sup>\u00ae<\/sup>-PRAME and DecisionDx<sup>\u00ae<\/sup>-UM<i>Seq<\/i>). For more information about Castle\u2019s gene expression profile tests, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.castletestinfo.com%2F&amp;esheet=52432717&amp;newsitemid=20210520005207&amp;lan=en-US&amp;anchor=www.CastleTestInfo.com&amp;index=2&amp;md5=d59f792f21d2e7cc80498662d6634906\">www.CastleTestInfo.com<\/a>. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcastlebiosciences.com%2F&amp;esheet=52432717&amp;newsitemid=20210520005207&amp;lan=en-US&amp;anchor=www.CastleBiosciences.com&amp;index=3&amp;md5=9bac7215854cea1f9dcce3c3199b7ca5\">www.CastleBiosciences.com<\/a>.\n<\/p>\n<p>\nDecisionDx-Melanoma, DecisionDx-CM<i>Seq<\/i>, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM<i>Seq<\/i> are trademarks of Castle Biosciences, Inc.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThe information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the \u201csafe harbor\u201d created by those sections. These forward-looking statements include, but are not limited to, statements concerning the ability of DecisionDx-SCC test results to accurately classify and predict the risk for metastasis in SCC patients with one or more risk factors, help avoid unnecessary treatment and surveillance, allow healthcare providers to increase treatment intensity or follow-up as needed and inform if and when to refer a patient for medical, surgical, or radiation oncology. The words \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business, subsequent study results and findings that contradict earlier study results and findings, our products\u2019 ability to provide the aforementioned benefits to patients and the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and in our other filings with the SEC.<i \/>The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210520005207\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210520005207\/en\/<\/a><\/span><\/p>\n<p>\nCamilla Zuckero<br \/>\n<br \/>832-835-5158<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:czuckero@castlebiosciences.com\">czuckero@castlebiosciences.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Other Science Research Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors Article in Journal of Drugs in Dermatology provides a framework for integrating DecisionDx-SCC into patient care FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert panel in the Journal of Drugs in Dermatology. The publication provides a framework for integrating DecisionDx-SCC into clinical practice. Treatment plan decisions in SCC are based upon the likelihood of an individual patient\u2019s tumor to metastasize. Data from previous studies has demonstrated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-496218","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors Article in Journal of Drugs in Dermatology provides a framework for integrating DecisionDx-SCC into patient care FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert panel in the Journal of Drugs in Dermatology. The publication provides a framework for integrating DecisionDx-SCC into clinical practice. Treatment plan decisions in SCC are based upon the likelihood of an individual patient\u2019s tumor to metastasize. Data from previous studies has demonstrated &hellip; Continue reading &quot;Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-20T11:03:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors\",\"datePublished\":\"2021-05-20T11:03:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/\"},\"wordCount\":1059,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/\",\"name\":\"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-05-20T11:03:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/","og_locale":"en_US","og_type":"article","og_title":"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors - Market Newsdesk","og_description":"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors Article in Journal of Drugs in Dermatology provides a framework for integrating DecisionDx-SCC into patient care FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert panel in the Journal of Drugs in Dermatology. The publication provides a framework for integrating DecisionDx-SCC into clinical practice. Treatment plan decisions in SCC are based upon the likelihood of an individual patient\u2019s tumor to metastasize. Data from previous studies has demonstrated &hellip; Continue reading \"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-20T11:03:30+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors","datePublished":"2021-05-20T11:03:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/"},"wordCount":1059,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/","name":"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-05-20T11:03:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005207r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/expert-panel-provides-framework-for-incorporating-decisiondx-scc-results-into-clinical-decision-making-for-cutaneous-squamous-cell-carcinoma-patients-with-one-or-more-risk-factors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/496218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=496218"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/496218\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=496218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=496218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=496218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}